RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

10/12/23 – RespireRx Pharmaceutical Inc’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services

October 12, 2023

8/9/23 – RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

August 9, 2023

5/24/23 – ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

May 24, 2023

NEWS: RespireRx Pharmaceutical Inc’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services

WATCH: RespireRx CSO Arnold Lippa Discusses Collaboration with University College London to Study Treatment Options for GRIA Disorders